Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity.

Compounds with excellent receptor engagement displaying α2-AR antagonist activity are useful not only for therapeutic purposes (e.g. antidepressants), but also to help in the crystallization of this particular GPCR. Therefore, based on our broad experience in the topic, we have prepared eighteen di-aryl (phenyl and/or pyridin-2-yl) mono- or di-substituted guanidines and 2-aminoimidazolines. The in vitro α2-AR binding affinity experiments in human brain tissue showed the advantage of a 2-aminoimidazolinium cation, a di-arylmethylene core, a conformationally locked pyridin-2-yl-guanidine and a di-substituted guanidinium to achieve good α2-AR engagement. After different in vitro [35S]GTPγS binding experiments in human prefrontal cortex tissue, it was possible to identify that compounds 7a, 7b and 7c were α2-AR partial agonist, whereas 8h was a potent α2-AR antagonist. Docking and MD studies with a model of α2A-AR and two crystal structures suggest that antagonism is achieved by compounds carrying a di-substituted guanidine which substituent occupy a pocket adjacent to TM5 without engaging S2005.42 or S2045.46, and a mono-substituted cationic group, which favorably interacts with E942.65. Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Citation

Michela McMullan, Brendan Kelly, Helene B Mihigo, Aaron P Keogh, Fernando Rodriguez, Iria Brocos-Mosquera, Aintzane García-Bea, Patricia Miranda-Azpiazu, Luis F Callado, Isabel Rozas. Di-aryl guanidinium derivatives: Towards improved α2-Adrenergic affinity and antagonist activity. European journal of medicinal chemistry. 2021 Jan 01;209:112947

Mesh Tags

Substances

PMID: 33139112

search → result